ATE513929T1 - Gene mit einfluss auf die menschliche gedächtnisleistung - Google Patents

Gene mit einfluss auf die menschliche gedächtnisleistung

Info

Publication number
ATE513929T1
ATE513929T1 AT07777651T AT07777651T ATE513929T1 AT E513929 T1 ATE513929 T1 AT E513929T1 AT 07777651 T AT07777651 T AT 07777651T AT 07777651 T AT07777651 T AT 07777651T AT E513929 T1 ATE513929 T1 AT E513929T1
Authority
AT
Austria
Prior art keywords
human memory
affecting human
memory performance
genes affecting
diseases
Prior art date
Application number
AT07777651T
Other languages
English (en)
Inventor
Andreas Papassotiropoulos
Dietrich Stephan
Quervain Dominique De
Original Assignee
Translational Genomics Res Inst
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Translational Genomics Res Inst, Univ Zuerich filed Critical Translational Genomics Res Inst
Application granted granted Critical
Publication of ATE513929T1 publication Critical patent/ATE513929T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07777651T 2006-01-27 2007-01-26 Gene mit einfluss auf die menschliche gedächtnisleistung ATE513929T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76271306P 2006-01-27 2006-01-27
US86219406P 2006-10-19 2006-10-19
PCT/US2007/061112 WO2007120955A2 (en) 2006-01-27 2007-01-26 Genes affecting human memory performance

Publications (1)

Publication Number Publication Date
ATE513929T1 true ATE513929T1 (de) 2011-07-15

Family

ID=38610268

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07777651T ATE513929T1 (de) 2006-01-27 2007-01-26 Gene mit einfluss auf die menschliche gedächtnisleistung

Country Status (7)

Country Link
US (1) US7993836B2 (de)
EP (1) EP1987165B1 (de)
JP (1) JP5191906B2 (de)
AT (1) ATE513929T1 (de)
AU (1) AU2007238541A1 (de)
CA (1) CA2638802A1 (de)
WO (1) WO2007120955A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008019395A2 (en) * 2006-08-10 2008-02-14 Translational Genomics Research Institute Compounds for improving learning and memory
TW201030337A (en) * 2009-02-04 2010-08-16 Tzu Chi Buddhist General Hospital Method and kit for detecting cancers
EP2354789A1 (de) 2010-02-08 2011-08-10 Sygnis Bioscience GmbH & Co. KG Verfahren zur Identifizierung von gedächtnismodulierenden Verbindungen durch Auswertung der KIBRA-Expression
WO2013041238A1 (en) * 2011-09-21 2013-03-28 Sygnis Bioscience Gmbh & Co. Kg Use of kibra peptides, hdac inhibitor or proteasome inhibitor for improving anxiety disorders
WO2013041239A1 (en) * 2011-09-21 2013-03-28 Sygnis Bioscience Gmbh & Co. Kg Pkm zeta bindin peptides, peptide derivatives and conjugates, and uses thereof
CN116925205A (zh) * 2022-04-07 2023-10-24 复旦大学 激活Hippo信号通路的多肽及其用途
CN114457154B (zh) * 2022-04-13 2022-06-28 山东第一医科大学附属省立医院(山东省立医院) KIBRA rs17070145检测试剂在制备嗅觉功能评价试剂盒中的应用
WO2024178151A2 (en) * 2023-02-22 2024-08-29 Buck Institute For Research On Aging Kibra peptides and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5993054A (ja) 1982-11-18 1984-05-29 Asahi Chem Ind Co Ltd イソキノリンスルホン酸アミド誘導体
US4678783B1 (en) 1983-11-04 1995-04-04 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds
EP0187371B1 (de) 1984-12-27 1991-06-19 Asahi Kasei Kogyo Kabushiki Kaisha Substituierte Isochinolinsulfonyl-Verbindungen
JPH0667926B2 (ja) 1985-11-12 1994-08-31 旭化成工業株式会社 環状のイソキノリンスルホンアミド誘導体
JP3464012B2 (ja) 1993-04-05 2003-11-05 旭化成株式会社 精神症候治療剤
EP0870767B1 (de) 1995-07-03 2000-02-16 Asahi Kasei Kogyo Kabushiki Kaisha 1-(5-isochinolinsulfonyl)homopiperazin hydrochlorid
CA2334120C (en) 1998-08-10 2006-10-17 Asahi Kasei Kogyo Kabushiki Kaisha Oral sustained-release preparation of fasudil hydrochloride
NZ524691A (en) 2000-09-14 2005-10-28 Univ Zuerich Calcium binding proteins
JP2007507204A (ja) * 2003-07-29 2007-03-29 ブリストル−マイヤーズ　スクイブ　カンパニー サイクリン依存性キナーゼモデュレーションのバイオマーカー
KR100565056B1 (ko) 2003-08-14 2006-03-30 삼성전자주식회사 Ａｖ 데이터를 ｅｎａｖ 모드로 재생하는 방법, 그 장치및 그 정보저장매체
WO2008019395A2 (en) 2006-08-10 2008-02-14 Translational Genomics Research Institute Compounds for improving learning and memory

Also Published As

Publication number Publication date
US7993836B2 (en) 2011-08-09
JP2009524437A (ja) 2009-07-02
US20090227500A1 (en) 2009-09-10
CA2638802A1 (en) 2007-10-25
WO2007120955A3 (en) 2008-02-14
EP1987165A4 (de) 2010-01-27
EP1987165A2 (de) 2008-11-05
AU2007238541A1 (en) 2007-10-25
JP5191906B2 (ja) 2013-05-08
WO2007120955A2 (en) 2007-10-25
EP1987165B1 (de) 2011-06-22

Similar Documents

Publication Publication Date Title
ATE513929T1 (de) Gene mit einfluss auf die menschliche gedächtnisleistung
MX2009012722A (es) Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
EA200800087A1 (ru) Генетические варианты гена tcf7l2 как диагностические маркеры риска возникновения сахарного диабета ii типа
WO2004066941A3 (en) Expression profiles for colon cancer and methods of use
EA200970891A1 (ru) Генетические варианты chr2 и chr16 в качестве маркеров для применения при оценке риска, диагностировании, прогнозировании и лечении рака молочной железы
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
HN2008000346A (es) Secuencias de nucleotidos que codifican proteinas insecticidas
ATE522626T1 (de) Verfahren und nukleotid-sequenzen, die bevorzugt die expression eines mutierten huntingtin-genes unterdrücken
AR061136A1 (es) Procedimiento
WO2005059108A3 (en) Gene expression profiles and methods of use
TW200740844A (en) Novel MAdCAM antibodies
WO2010004591A3 (en) Genetic variants for breast cancer risk assessment
MX2010001993A (es) Metodos y composiciones para diagnosticar una enfermedad.
EA201270574A1 (ru) Способы и системы для фармакогеномного лечения сердечно-сосудистых заболеваний
WO2010011283A3 (en) Fus/tls-based compounds and methods for diagnosis, treatment and prevention of amyotrophic lateral sclerosis and related motor neuron diseases
ATE534738T1 (de) Mir-126-regulierte gene und pfade als ziele für therapeutische interventionen
WO2004078035A3 (en) Expression profiles for breast cancer and methods of use
MX2008013397A (es) Analisis de perfilamiento de expresion diferencial de fenotipos de cultivo celular y usos de los mismos.
DK1730315T3 (da) Polymorphismer i NOD2/Card15 gen
BRPI0512745A (pt) métodos de genotipagem e de caracterizar um agente e kit
WO2007058968A3 (en) Gene expression profiles and methods of use
NO20021146D0 (no) Polymorfier i de humane CYP3A4- og CYP3A7-genene og deres anvendelse i diagnostiske og terapeutiske anvendelser
ATE482976T1 (de) Defensinproteine
WO2007084359A3 (en) Compositions and methods for the treatment of influenza infection

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1987165

Country of ref document: EP